Clinical trials: Graves Orbitopathy
Thyroid Eye Disease
An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease
- Trial name
- NCT07462130
- Testing
- NTB003
- Volunteers
- 74 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Graves Ophthalmopathy
Genetics and Epigenetics of Graves' Orbitopathy
Graves' orbitopathy (GO) is an autoimmune disease persisting when immunosuppression is achieved. Orbital fibroblasts from GO patients display peculiar phenotypes even if not exposed to autoimmunity, possibly reflecting genetic or…
- Trial name
- GeneGO (NCT04488406)
- Testing
- No Intervention
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease.
- Trial name
- NCT06359795
- Testing
- 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Thyroid Associated Orbitopathy
Changes in Orbital Macrovascular and Intraocular Microvascular Blood Flow After Orbital Decompression Surgery in Patients With Thyroid Eye Disease
This study aims to evaluate the effects of balanced orbital decompression surgery in patients with inactive thyroid-associated orbitopathy.
- Trial name
- BOD-VASC (NCT07393230)
- Testing
- Balanced Orbital Decompression Surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)
This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED: 1. β- Carotene (30 mg) 2. Vit C (100 mg) 3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU 4.
- Trial name
- NCT02393183
- Testing
- ASTED, Selenium
- Where
- Iran
- Sponsor
- Iran University of Medical Sciences
Thyroid Associated Ophthalmopathy
Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy
This study aims to develop the deep learning-based system that integrates multimodal information to automatically diagnose, stage, and grade thyroid-associated ophthalmopathy (TAO), assist in treatment decision-making, and…
- Trial name
- NCT07124572
- Testing
- Imaging and ocular examinations
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ocular Motility Disorders, Strabismus
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)
This prospective, multicenter, multinational observational study evaluates the clinical validity of an AI-based quantitative eye movement analysis system (Glandy EOM) that analyzes smartphone-recorded 9-gaze videos.
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Trial name
- GLANDY-EOM-VAL (NCT07623837)
- Testing
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- THYROSCOPE INC.
Thyroid Eye Disease (TED)
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
- Trial name
- RECLAIM (NCT07404111)
- Testing
- VV-14305
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 135 people
- Sponsor
- Kriya Therapeutics, Inc.
Graves' Orbitopathy
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation.
- Trial name
- ABLAGO (NCT04776993)
- Testing
- Methimazole, Radioiodine or thyroidectomy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Graves Ophthalmopathy
Sirolimus for Graves' Orbitopathy (GO)
Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast…
- Trial name
- SIRGO (NCT04598815)
- Testing
- Sirolimus
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Thyroid-Associated Ophthalmopathy
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with…
- Trial name
- NCT00288522
- Testing
- Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Ipsen
Thyroid Eye Disease (TED), Graves Ophthalmopathy
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical…
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Trial name
- THYROSCOPE-TED (NCT07623993)
- Testing
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- THYROSCOPE INC.
Graves Disease, Immunoglobulin
TSI and Its Relationship With Graves' Disease Relapse
The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD).
- Conditions
- Graves Disease, Immunoglobulin, Anti-Thyroid Antibodies Disorder
- Trial name
- NCT05713097
- Testing
- TSI
- Where
- Vietnam
- Volunteers
- 352 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Thyroid Eye Disease
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but…
- Trial name
- NCT07832136
- Testing
- veligrotrug (LUMVOA™)
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Keratoconus, Corneal Ectasia
Corneal Tomographic Parameters in TGD
The current study involved analysis of the corneal tomographic parameters of patients with thyroid gland dysfunction (hyperthyroidism or hypothyroidism), including those with an autoimmune etiology, in comparison to healthy…
- Conditions
- Keratoconus, Corneal Ectasia, Thyroid Eye Disease
- Trial name
- NCT04433936
- Testing
- Pentacam tomography
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ameera Gamal Abdelhameed
Thyroid Associated Ophthalmopathies
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152392
- Testing
- IBI311, Follew-up
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease, Graves' Orbitopathy
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody [mAb] inhibitor of the insulin-like growth factor-1 receptor [IGF-1R]) administered once every 3…
- Trial name
- OPTIC (NCT03298867)
- Testing
- Teprotumumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Amgen
Graves Ophthalmopathy
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
Autoimmune ophthalmopathy is clinically evident in one third of Graves' disease cases. In most cases it is mild; however, in 3 to 5% of cases it has a severe presentation.
- Trial name
- NCT01893450
- Testing
- Methimazole, Bromocriptine, Pentoxifylline
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran